Visiting Scientist — Division of Genetic and Molecular Toxicology
No photo available
Rui Xiong, Ph.D.
Dr. Rui Xiong received her Ph.D. in toxicology from the University of Colorado Anschutz Medical Campus in 2015, specializing in quinone toxicity and quinone-based small molecule drug discovery. She joined NCTR/DGMT as an ORISE Postdoctoral Fellow in 2015 and worked on FDA Center for Tobacco Products (CTP)-funded projects evaluating the toxicological effects of tobacco smoke and its constituents using in vitro human airway tissue models, information necessary for the regulatory review of tobacco product applications. Dr. Xiong was converted to an FDA visiting scientist in 2018 and continued work on several tobacco-related projects. She also collaborates with the FDA Center for Biologics Evaluation and Research (CBER) to study the virulence mechanisms of Bordetella pertussis using an in vitro human air-liquid-interface (ALI) airway model. Dr. Xiong has extensive experience with running cigarette smoking robots as well as developing in vitro methods for toxicity assessment. She has received multiple awards for her research, including the Regulatory and Safety Evaluation Specialty Section Postdoc Excellence Award from the Society of Toxicology, the Post-Doc Award from the International Society of Regulatory Toxicology and Pharmacology, and FDA and NCTR group recognition awards.
Dr. Xiong’s research interests involve the development and application of advanced in vitro human airway tissue models for toxicity assessment of human respiratory pathogens as well as xenobiotics including drug candidates, tobacco smoke, and environmental toxins. She also is interested in combining in vitro tissue models with computational modeling extrapolation strategies to make quantitative human risk assessments.
Professional Societies/National and International Groups
Society of Toxicology
2012 – Present
Dr. Daniel Acosta and In Vitro Toxicology at the U.S. Food and Drug Administration’s National Center for Toxicological Research.
Inselman A., Liu F., Wang C., Shi Q., Pang L., Mattes W., White M., Lyn-Cook B., Rosas-Hernandez H., Cuevas E., Lantz S., Imam S., Ali S., Petibone D.M., Shemansky J.M., Xiong R., Wang Y., Tripathi P., Cao X., Heflich R.H., and Slikker W. Jr.
Toxicol In Vitro. 2020, 64:104471.
Evaluating Mode of Action of Acrolein Toxicity in an In Vitro Human Airway Tissue Model.
Xiong R., Wu Q., Muskhelishvili L., Davis K., Shemansky J., Bryant M., Rosenfeldt H., Healy S.M., and Cao X.
Toxicol Sci. 2018, 166(2):451-464.
Disease-Related Responses Induced by Cadmium in an In Vitro Human Airway Tissue Model.
Xiong R., Wu Q., Trbojevich R., Muskhelishvili L., Davis K., Bryant M., Richter P., and Cao X.,
Toxicol Lett. 2019, 303:16-27.
Effects of Cellular Differentiation in Human Primary Bronchial Epithelial Cells: Metabolism of 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone.
Qin Q., Wu Q., Wang Y., Xiong R., Guo L., Fu X., Rosenfeldt H., Bryant M., and Cao X.
Toxicol In Vitro. 2019, 55:185-194.
A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T Alpha-synuclein Toxicity.
Xiong R., Zhou W.B., Siegel D., Kitson R.R., Moody C.J., and Ross D.
Mol Pharmacol. 2015, 88(6):1045-54.
Quinone-Induced Protein Handling Changes: Implications for Major Protein Handling Systems in Quinone-Mediated Toxicity.
Xiong R., Siegel D., and Ross D.,
Toxicol Appl Pharmacol. 2014, 280: 285–295.
The Activation Sequence of Cellular Protein Handling Systems After Proteasomal Inhibition in Dopaminergic Cells.
Xiong R., Siegel D., and Ross D.
Chem Biol Interact. 2013, 204(2):116-24.
Synthesis of 19-Substituted Geldanamycins with Altered Conformations and Their Binding to Heat Shock Protein Hsp90.
Kitson R.R., Chang C.H., Xiong R., Williams H.E., Davis A.L., Lewis W., Dehn D.L., Siegel D., Roe S.M., Prodromou C., Ross D., and Moody C.J.
Nat Chem. 2013, 5(4):307-14.
- Contact Information
- Rui Xiong
ExpertiseApproachDomainCarcinogenicityTechnology & DisciplineToxicology